TLDR Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
This study evaluated the potential dementia risk associated with alpha-blockers and 5-alpha reductase inhibitors (5ARIs) in patients with benign prostatic hyperplasia (BPH) by analyzing data from 5 multicenter studies involving 3,650,434 patients. The results indicated no significant association between these medications and an increased risk of dementia. However, 5ARIs showed a relatively higher probability of dementia risk compared to other treatments. The findings suggest that these medications can be prescribed without significant concern for dementia risk, but further large-scale research is recommended to confirm these results.
December 2022 in “JAMA network open” 5α-Reductase inhibitors may increase depression risk but not dementia or suicide.
18 citations
,
June 2017 in “Journal of the neurological sciences” Using 5 alpha reductase inhibitors may increase dementia risk in the first two years.
2 citations
,
September 2009 in “Hormone Molecular Biology and Clinical Investigation” Low dose finasteride decreases certain steroids, possibly increasing depression risk.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
18 citations
,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
77 citations
,
June 2015 in “Nature Reviews Urology” Some common medications can harm male fertility, but many effects can be reversed.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.